Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
09:30am, Monday, 25'th Nov 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebs
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opi
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and el
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
11:29am, Tuesday, 05'th Nov 2024
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
11:12pm, Thursday, 31'st Oct 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief E
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
06:20pm, Thursday, 31'st Oct 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.22 per share a year ago.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
04:30pm, Thursday, 17'th Oct 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30,
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
04:00pm, Thursday, 03'rd Oct 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in
Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High?
10:55am, Tuesday, 06'th Aug 2024
The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
09:15am, Tuesday, 06'th Aug 2024
24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
10:10pm, Thursday, 01'st Aug 2024
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Exe
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
06:51pm, Thursday, 01'st Aug 2024
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.45 per share a year ago.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The positive preli
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
04:05pm, Thursday, 18'th Jul 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Comp
